Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Technetium 99m tetrofosmin - GE Healthcare

Next Previous
Search
Drug Profile

Technetium 99m tetrofosmin - GE Healthcare

Alternative Names: 99mTc-tetrofosmin; Myoview; MYOVIEW 30mL; MYOVIEW24; PPN-1011; Tc-99m Tetrofosmin; Tc-99m tetrofosmin SPECT; Tc-99m-PPN1011; Technetium (99MTC) Tetrofosmin; Technetium-Tm99m-tetrofosmin

Latest Information Update: 30 Sep 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amersham
  • Developer Amersham; GE Healthcare
  • Class Heavy metals; Imaging agents; Phosphorus compounds; Radiopharmaceutical diagnostics; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Coronary disorders; Ischaemia
  • Discontinued Brain cancer

Most Recent Events

  • 30 Sep 2019 Discontinued - Phase-II for Brain cancer (Diagnosis, In the elderly, In adults) in Germany (IV)
  • 07 Jun 2016 Chemical information added
  • 26 Apr 2016 Phase II clinical trials in Brain cancer (Diagnosis, In adults, In the elderly) in Germany (IV) (EudraCT2015-005573-21)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top